Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma. Background: PCL, a rare manifestation of symptomatic multiple myeloma (MM), has a dismal prognosis.
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback